Postponement of release of Annual Results and Voluntary Trading Statement
Ascendis Health Limited
(Incorporated in the Republic of South Africa)
(Registration number 2008/005856/06)
Share code: ASC
(“Ascendis” or “the group”)
POSTPONEMENT OF RELEASE OF ANNUAL RESULTS AND VOLUNTARY TRADING
Postponement of release of annual results
Shareholders are advised that the group’s annual results for the year ended 30 June 2018, which were
scheduled to be released on 11 September 2018, will now be released on SENS on 25 September
The postponement is due to unexpected delays in finalising the annual results following the
implementation of a new financial reporting system late in the financial year.
The board and management apologise for the inconvenience caused by the delay in the release of the
results and the related investor presentations. The annual results and strategy presentations will now
be held in Johannesburg on 25 September 2018 and in Cape Town on 26 September.
Voluntary trading statement for the year ended 30 June 2018
Ascendis shareholders are advised that the group’s earnings for the year ended 30 June 2018 are
anticipated to be within the following ranges:
Continuing Operations 12 months ended 12 months ended
30 June 2018 30 June 2017 % increase
Basic earnings per share 96.4 – 102.9 cents 85.9 cents 12% – 20%
Headline earnings per share 102.7 – 109.2 cents 90.8 cents 13% - 20%
Normalised headline earnings per share 157.8 – 164.3 cents 156.4 cents 1% – 5%
Total Operations 12 months ended 12 months ended %
30 June 2018 30 June 2017 (decrease)/
Basic earnings per share 55.7 – 62.2 cents 68.7 cents (19%) – (9%)
Headline earnings per share 74.5 – 81.0 cents 80.1 cents (7%) - 1%
Normalised headline earnings per share 132.3 – 138.8 cents 145.7 cents (9%) - (5%)
1. As announced on SENS on 25 June 2018, the group has disposed of Ascendis Sports Nutrition
South Africa and Ascendis Direct Selling and these businesses have been classified as
2. The results include the acquisition of Kyron Laboratories (“Kyron”) with effect from 1 March
3. Normalised headline earnings per share from continuing operations comprise headline
earnings per share from continuing operations adjusted for once-off costs of approximately
R83 million (R177 million in the comparative period to June 2017) as well as amortisation costs.
Shareholders are referred to the annual financial statements for the financial year ended
30 June 2017 for further information in respect of the normalisation adjustments.
4. Shareholders are reminded of the clarification provided by the Company on SENS on
1 February 2018 clarifying the amendment in its methodology in calculating normalised
earnings per share. This change in methodology was not applied to the comparative normalised
earnings per share figure presented above for the year ended 30 June 2017. Should the
company have applied the revised methodology to the comparative figure, the normalised
earnings per share from continuing operations for the year ended 30 June 2017 would have
been 144.8 cents per share.
The financial information on which this trading statement is based has not been reviewed or reported
on by the group’s auditors.
7 September 2018
Questco Corporate Advisory (Pty) Ltd
Date: 07/09/2018 05:35:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Email this JSE Sens Item to a Friend.